Search

Your search keyword '"Digiesi, Giovanna"' showing total 25 results
Start Over Author "Digiesi, Giovanna"
25 results on '"Digiesi, Giovanna"'

8. Cost‐effectiveness in transient hypocalcemia post‐thyroidectomy

Author

Mercante, Giuseppe, primary, Anelli, Andrea, additional, Giannarelli, Diana, additional, Giordano, Davide, additional, Sinopoli, Ilenia, additional, Ferreli, Fabio, additional, Digiesi, Giovanna, additional, Appetecchia, Maria L., additional, Barnabei, Agnese, additional, Cristalli, Giovanni, additional, Conti, Laura, additional, Pellini, Raul, additional, Piazza, Fabio, additional, Lombardi, Davide, additional, De Virgilio, Armando, additional, and Spriano, Giuseppe, additional

Published
2019
Full Text
View/download PDF

9. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

Author

Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

In recent years, the poorly remarkable goals achieved in terms of patients’ important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 µm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.

Published
2018

10. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

Author

Pizzuti, Laura, primary, Sergi, Domenico, additional, Mandoj, Chiara, additional, Antoniani, Barbara, additional, Sperati, Francesca, additional, Chirico, Andrea, additional, Di Lauro, Luigi, additional, Valle, Mario, additional, Garofalo, Alfredo, additional, Vizza, Enrico, additional, Corrado, Giacomo, additional, Tomao, Federica, additional, Rinaldi, Massimo, additional, Carpano, Silvia, additional, Maugeri‐Saccà, Marcello, additional, Conti, Laura, additional, Digiesi, Giovanna, additional, Marchetti, Paolo, additional, De Maria, Ruggero, additional, Giordano, Antonio, additional, Barba, Maddalena, additional, Carosi, Maria A., additional, and Vici, Patrizia, additional

Published
2017
Full Text
View/download PDF

12. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients

Author

Vici, Patrizia, primary, Pizzuti, Laura, additional, Di Lauro, Luigi, additional, Conti, Laura, additional, Mandoj, Chiara, additional, Antenucci, Anna, additional, Digiesi, Giovanna, additional, Sergi, Domenico, additional, Amodio, Antonella, additional, Marchetti, Paolo, additional, Sperati, Francesca, additional, Valle, Mario, additional, Garofalo, Alfredo, additional, Vizza, Enrico, additional, Corrado, Giacomo, additional, Vincenzoni, Cristina, additional, Tomao, Federica, additional, Kayal, Ramy, additional, Marsella, Annalise, additional, Carosi, Mariantonia, additional, Antoniani, Barbara, additional, Giordano, Antonio, additional, Maugeri-Saccà, Marcello, additional, and Barba, Maddalena, additional

Published
2016
Full Text
View/download PDF

18. Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Author

Molica, Stefano, primary, Vitelli, Gaetano, primary, Cutrona, Giovanna, primary, Mirabelli, Rosanna, primary, Digiesi, Giovanna, primary, Giannarelli, Diana, primary, Sperduti, Isabella, primary, Morabito, Fortunato, primary, and Ferrarini, Manlio, primary

Published
2008
Full Text
View/download PDF

19. Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia

Author

Molica, Stefano, primary, Vitelli, Gaetano, additional, Cutrona, Giovanna, additional, Todoerti, Katia, additional, Mirabelli, Rosanna, additional, Digiesi, Giovanna, additional, Morabito, Fortunato, additional, Neri, Antonino, additional, and Ferrarini, Manlio, additional

Published
2008
Full Text
View/download PDF

20. Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Author

Molica, Stefano, primary, Vitelli, Gaetano, additional, Cutrona, Giovanna, additional, Digiesi, Giovanna, additional, Mirabelli, Rosanna, additional, Giannarelli, Diana, additional, Sperduti, Isabella, additional, and Ferrarini, Manlio, additional

Published
2007
Full Text
View/download PDF

25. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.

Author

Pizzuti L, Sergi D, Mandoj C, Antoniani B, Sperati F, Chirico A, Di Lauro L, Valle M, Garofalo A, Vizza E, Corrado G, Tomao F, Rinaldi M, Carpano S, Maugeri-Saccà M, Conti L, Digiesi G, Marchetti P, De Maria R, Giordano A, Barba M, Carosi MA, and Vici P

Subjects
Adult, Aged, Biopsy, Cystadenocarcinoma, Serous blood, Cystadenocarcinoma, Serous pathology, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Grading, Observer Variation, Ovarian Neoplasms blood, Ovarian Neoplasms pathology, Reproducibility of Results, Biomarkers, Tumor analysis, Blood Glucose analysis, Cystadenocarcinoma, Serous chemistry, Fasting blood, Glucose Transporter Type 1 analysis, Ovarian Neoplasms chemistry
Abstract

In recent years, the poorly remarkable goals achieved in terms of patients' important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 µm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer., (© 2017 Wiley Periodicals, Inc.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results